Therefore, targeted inhibition of USP36 to block PrimPol-mediated replication fork restart, combined with the use of DNA replication stress pathway inhibitors, may enhance the chemosensitivity of ovarian cancer cells, providing a novel approach for ovarian cancer treatment. Here, USP36 is linked to ovarian carcinoma.